Gemfibrozil is in the fibric acid derivatives drug class, which inhibits the production of very-low-density lipoproteins (VLDLs) and enhances VLDL clearance by stimulating lipoprotein lipase activity. This primarily results in reducing triglycerides and raising HDL-C. One of the earlier trials, the Helsinki Heart Study, assessed the impact of gemfibrozil in middle-aged men with dyslipidemia (non-HDL ? 200 mg/dL). In this placebo-controlled randomized control trial 600 mg of gemfibrozil two times daily for 5 years resulted in an increase of HDL-C by more than 10% and a reduction in total cholesterol, LDL cholesterol, non-HDL cholesterol, and triglycerides by 8%, 8%, 12%, and 35%, respectively. The primary end points of coronary heart disease—fatal and nonfatal myocardial infarction and cardiac death—incidence was reduced by 34%.

When will you take the gempill, /sci/?